{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020128","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.539443+00:00","generated_at":"2026-06-01T19:19:36.264177+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation","bullets":["ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.","Partnering with Avance Clinical for Phase IIa at level one trauma centers in Australia.","Formulation optimized to increase active compound percentage and target brain absorption within minutes.","Estimated 69 million concussion cases globally annually; up to 20% develop post-concussion syndrome.","Adequate intranasal device supply secured for upcoming trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020128","json":"https://secwatch.observer/filing/0001493152-24-020128.json","markdown":"https://secwatch.observer/filing/0001493152-24-020128.md","text":"https://secwatch.observer/filing/0001493152-24-020128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/0001493152-24-020128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:19:36.264177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}